Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;18(4):258-264.
doi: 10.1200/OP.21.00240. Epub 2021 Oct 15.

Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors

Affiliations
Review

Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors

Janie Y Zhang et al. JCO Oncol Pract. 2022 Apr.

Abstract

Neuroendocrine tumors (NETs) are a heterogeneous clinical entity with a broad range of grade, pace of disease, functional status, and primary sites. Pathologic classification, diagnostic modalities, and therapeutic options for NETs have evolved considerably in the past decade. In part driven by these advances, incidence and prevalence of NETs are rising in the United States and the practicing oncologist is likely to encounter these in the clinic. However, there are no clear lines of therapy for unresectable or metastatic NETs, and sequencing of systemic therapies depends on consideration of patient and tumor characteristics including extent of disease, grade, pace of growth, functional status, primary site, somatostatin receptor status, performance status, and comorbidities. Familiarity with ongoing clinical trials will guide therapeutic decision making as well. In this review, we seek to provide a framework to formulate and tailor an individualized treatment plan for each patient with a NET.

PubMed Disclaimer

Conflict of interest statement

Pamela L. KunzStock and Other Ownership Interests: Guardant HealthConsulting or Advisory Role: Ipsen, Lexicon, Sun Pharma, Acrotech Biopharma, Novartis (Advanced Accelerator Applications), Genentech/Roche, Amgen, Crinetics PharmaceuticalsResearch Funding: Lexicon, Ipsen, Xencor, Brahms, Novartis (Advanced Accelerator Applications)Open Payments Link: https://openpaymentsdata.cms.gov/physician/191388No other potential conflicts of interest were reported.

MeSH terms

LinkOut - more resources